HCW Biologics signs exclusive distribution deal with Akron Biotech for HCW11-006
The agreement covers a five-year, worldwide (excluding China) distribution arrangement for HCW11-006 as a CAR-T manufacturing reagent, with closing set for no later than November 30, 2026.
HCW Biologics Inc. (NASDAQ: HCWB) entered into an Exclusive Distribution Agreement with Akron Biotech on September 4, 2026, covering worldwide distribution of HCW11-006 as a reagent for cell therapy manufacturing and other ex vivo applications, excluding use in injectable therapies, for a five-year term throughout the world except the People's Republic of China1. The company disclosed the agreement in an 8-K filing and accompanying press release dated September 8, 2026.
Akron Biotech is described as operating within a specialized global network of biomedical institutions, primarily serving advanced therapy developers, biopharmaceutical companies, and research organizations1. According to the filing, Akron produces and sells ancillary materials that meet cGMP standards, including items like cytokines, media supplements, and plasmid DNA, which are needed to move regenerative medicine products from preclinical development through commercialization1.
Under the deal, the parties will sign a Material Transfer Agreement so Akron can conduct further due diligence and product testing, with closing subject to satisfactory completion of that diligence but occurring no later than November 30, 20261. Following closing, the parties agreed to negotiate a Supply Agreement within 60 days, under which HCW Biologics would receive $200,000 at closing, $100,000 within 30 days of the Supply Agreement's execution, and $100,000 on each of the first and second anniversaries of closing1. Akron will also make quarterly payments to HCW Biologics for technical support as needed1.
If HCW Biologics terminates the agreement early for convenience, the company has committed to continue supplying the product to support existing Akron customers, among other transition provisions1.
HCW11-006 is described in the filing as a first-in-class multi-cytokine fusion molecule built on the company's TRBC platform, intended to support production of CAR-T cells enriched for long-lived T-memory stem cells1. Clinical studies are planned to further confirm preclinical findings1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.